12/31/2009 | CV | Celldex assumes obligations of CuraGen's 4% convertibles after merger
|
10/2/2009 | CV | CuraGen amends indenture of 4% convertibles following Celldex merger
|
10/2/2009 | SS | CuraGen becomes wholly owned subsidiary of Celldex Therapeutics
|
8/28/2009 | SS | Celldex Therapeutics, CuraGen shareholders to vote on merger Sept. 30
|
7/31/2009 | CV | CuraGen buys back $1.64 million 4% convertibles subordinated notes
|
6/22/2009 | SS | CuraGen investor DellaCamera sells shares, cuts ownership to 4.5%
|
5/29/2009 | SS | Market Commentary: AOL to add board within months; Celldex gains CuraGen cash; FiberNet counter bid predicted
|
5/14/2008 | CV | CuraGen buys back $50.9 million of 4% convertibles
|
11/15/2007 | CV | CuraGen buys back $22.2 million 4% convertibles
|
3/29/2007 | SS | Market Commentary: Lone Star deal propels Ipsco, others; Tribune rises; Riviera recoils; IMAX off; CuraGen dives
|
10/26/2006 | BT | CuraGen to make development decisions on lead products in 2007
|
8/24/2006 | BT | CuraGen, TopoTarget: Southwest Oncology Group starts lymphoma trial
|
8/10/2006 | BT | CuraGen, TopoTarget begin phase 1 trial for using oral PXD101 to treat solid tumors
|
8/8/2006 | BT | CuraGen, TopoTarget start PXD101 and azacitidine trial to treat blood cancers
|
7/27/2006 | BT | CuraGen reports second-quarter net loss of $14.3 million
|
7/19/2006 | BT | CuraGen to receive royalties on Bayer's licensing of BAY 76-7171 for diabetes management
|
7/14/2006 | BT | CuraGen, TopoTarget begin phase 1/ 2 trial of PXD101 for liver cancer
|
6/26/2006 | BT | CuraGen: New method can detect cancer gene mutations at low levels
|
6/22/2006 | BT | CuraGen begins phase 1 trial with CR011-vcMMAE for metastatic melanoma
|
6/22/2006 | BT | CuraGen says it will select drug candidates for regulatory development by end of 2007
|
6/20/2006 | BT | CuraGen, TopoTarget begin patient dosing in phase 2 trial of PXD101 for treatment of mesothelioma
|
6/14/2006 | BT | CuraGen, TopoTarget begin phase 1 trial of PXD101, cis-retinoic acid in solid tumors
|
6/6/2006 | BT | CuraGen, TopoTarget start phase 2 trial of PXD101 for acute myelogenous leukemia
|
5/30/2006 | BT | CuraGen starts second phase 2 velafermin trial
|
5/19/2006 | CV | Market Commentary: SafeNet improves dollar-neutral on federal probe; American Axle likely to be converted, analyst says
|
4/26/2006 | BT | CuraGen, Roche Diagnostics launch updated version of the Genome Sequencer 20 System
|
4/6/2006 | BT | CuraGen, TopoTarget present preclinical data on PXD101 at the AACR meeting
|
3/29/2006 | BT | CuraGen, TopoTarget begin clinical trial with PXD101 to treat tumors, lymphoma
|
3/22/2006 | BT | CuraGen, TopoTarget starts phase 1b/2 trial of PXD101 and Velcade to treat blood cancer
|
2/21/2006 | BT | Further data from CuraGen's phase 2 trial on velafermin show efficacy at lowest dose
|
2/21/2006 | BT | Market Commentary: Alnylam up 10% on Novartis pact; OSI off; CuraGen clipped; Inspire comes in; Ista drops despite data
|
2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
2/1/2006 | BT | CuraGen, TopoTarget begin phase 2 clinical trial of PXD101 for lymphoma
|
12/20/2005 | BT | CuraGen opts for tiered royalties, drops development costs in Bayer collaboration
|
12/20/2005 | BT | Market Commentary: Connetics rebounds to end higher; SeraCare plunges 48%; OraSure gains 8%; CuraGen rises by 4%
|
12/13/2005 | BT | CuraGen tests show velafermin reduces oral mucositis, but tests not statistically significant
|
12/13/2005 | BT | Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
|
12/13/2005 | CV | Market Commentary: Omnicare edges higher; Intel, Ceradyne on deck; price talk emerges on Entergy mandatories
|
12/12/2005 | BT | CuraGen, TopoTarget says PXD101 well tolerated, shows potential activity in phase 1 trial
|
11/18/2005 | BT | CuraGen, TopoTarget PXD101 well tolerated, shows some antitumor activity as single agent
|
11/14/2005 | BT | CuraGen says CR002 phase 1 study shows potential to treat kidney inflammation associated with PDGF-D
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/20/2005 | BTCV | CuraGen buys back $23.9 million 6% convertibles
|
9/8/2005 | CV | Market Commentary: Convertibles trade mixed, with Amgen, Nabors edging up, Cypress Semiconductor down
|
9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
8/10/2005 | BT | New Issue: CuraGen raises $22 million in follow-on at $5.50, discounted from $6.06 close
|
8/10/2005 | BT | Market Commentary: Coley, China Medical IPOs zoom out of gate; CuraGen off due to follow-on; Electro-Optical on hold
|
8/10/2005 | CV | CuraGen to repurchase convertibles using stock offering proceeds
|
7/25/2005 | BTCV | CuraGen buys back $39.9 million 6% convertibles due 2007 for $37.7 million
|
7/8/2005 | CV | Market Commentary: Biotechs, chips lead convertibles mostly higher; Charming Shoppes, Henry Schein trade higher
|
5/12/2005 | CV | Market Commentary: GM, Ford head renewed move south; Delta convertibles idle after 7.7s swapped for equity
|
4/26/2005 | CV | Market Commentary: Curagen plunges amid big sellout; Level 3 founders; XM rises, Sirius dips; Wynn bid up; airlines plunge
|
3/15/2005 | CV | Market Commentary: Central Parking up; Whole Foods off as Wild Oats rises; Ivax better, Curagen slides; Leucadia easier
|
10/19/2004 | CV | Market Commentary: Delta convertibles dive 1 point each; Jakks Pacific slammed by lawsuit; Ford, GM off
|
10/13/2004 | CV | Market Commentary: Delta convertibles rise sharply; Amkor buyers heartened; Lucent edges up, Apex easier
|
4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
3/16/2004 | CV | CuraGen greenshoe partially exercised, raising convertibles to $110 million
|
2/12/2004 | CVDD | S&P rates CuraGen converts CCC
|
2/11/2004 | CV | New Issue: CuraGen upsized $100 million convertible yields 4.0%, up 37%
|
2/11/2004 | CV | Market Commentary: Disney steals show; Echostar cast as takeover target, too; Safeguard advanced
|
2/10/2004 | CV | Market Commentary: New deals active; Solectron loses 0.5 point; AMR reoffered at 98.5; CuraGen, InterMune ahead
|
2/9/2004 | CV | CuraGen $75 million convertible talked at 3.75-4.25% yield, up 33-37%
|
2/9/2004 | CV | Market Commentary: Calpine 4s add 1.25 points on tender; Juniper whacked 11.25 points; four deals tossed to market
|
11/10/2003 | CV | Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market
|